Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study
Table 1
Study population baseline characteristics before and after propensity matching.
Variable
Before propensity score matching
After propensity score matching
DAB
VKA
P value
DAB
VKA
P value
(n = 389)
(n = 510)
(n = 175)
(n = 175)
Age (years)
65.1 ± 10.1
75.8 ± 6.5
<0.001
60.2 ± 12.0
62.2 ± 11.5
0.83
Female (%)
42.8
43.1
0.68
43.07
42.09
0.71
BMI (kg/m2)
27.8 ± 7.1
27.9 ± 7.1
0.82
27.8 ± 6.1
28.8 ± 6.1
0.78
Hypertension (%)
48.5
59.1
0.001
50.2
49.9
0.57
CHA2DS2-VASc score
3.3 ± 1.5
4.1 ± 1.4
0.02
3.5 ± 1.4
3.4 ± 1.6
0.55
HAS-BLED score
2.1 ± 1.2
3.1 ±1.1
0.001
2.03 ± 1.2
2.05 ±1.4
0.55
Diabetes mellitus (%)
12
20
0.06
12
11
0.4
Heart failure (%)
19.8
28.2
0.001
20.9
21.2
0.8
Prior stroke/TIA (%)
28.6
38.2
0.001
28.7
27.8
0.6
Prior MI (%)
7.1
13.1
0.02
5.5
6.3
0.6
CrCl (ml/min)
70.2 ± 19.1
61.2 ± 14.5
0.001
70.2 ± 22.1
73.1 ± 20.2
0.7
LAD (mm)
45.3 ± 5.9
46.4 ± 5.8
0.8
46.1 ± 6.3
47.2 ± 5.2
0.8
LAVI (ml/m2)
32.1 ± 1.1
34.2 ± 0.9
0.42
32.7 ± 2.2
33.5 ± 1.1
0.7
LVEF (%)
55.3 ± 8.5
45.2 ± 7.1
0.001
55.2 ± 5.2
53.2 ± 4.2
0.8
Values are mean ± SD unless otherwise stated. BMI: body mass index, CrCl: creatinine clearance, DAB: dabigatran etexilate, LAD: left atrial diameter, LAVI:indexed left atrial volume, LVEF: left ventricle ejection fraction, MI: myocardial infarction, SD: standard deviation, TIA: transient ischemic attack, and VKA: vitamin K antagonist.
